Category: C.R. Bard
ConvaTec is reportedly weighing a sale of the private-equity-owned medical device company next year, even as interest in a Medtronic-like inversion deal mounts from C.R. Bard, CareFusion and 3M.
Here's a look at some of the top legal news stories for medical device companies this week: Boston Scientific prevails in 1st pelvic mesh trial; Bard settles more than 500 pelvic mesh complaints; Edwards: Q2 brings double-digit sales bump, a major Medtronic settlement and a rosier outlook on the year; Ex-sales rep's counter-claims stand in poaching spat with Stryker; ResMed kicks Apex sleep masks out of Germany
Here's a look at some of the top Wall Street stories for medical device companies this week: Smith & Nephew CEO reveals new 'no frills' strategy; Bard: We're on track for early 2015 Lutonix approval; Ocular Therapeutix prices IPO below range; Philips' healthcare business suffers in Q2; Intersect ENT prices IPO at low end of range
A recent spate of mega-mergers hasn't inspired medtech peers to follow suit just yet, according to leadership at Boston Scientific, C.R. Bard and Smith & Nephew.
The medical device industry has some blockbuster merger activity in recent months, but a few companies are sitting this one out.
C.R. Bard closes the books on more than 500 patient injury complaints associated with its Avaulta pelvic mesh implants for an undisclosed amount.
C.R. Bard (NYSE:BCR) managed to close the books on a large chunk of patient complaints against its Avaulta mesh implant, settling more than 500 cases in its 2nd quarter.
Executives at C.R. Bard say the company is on track for an early 2015 approval for its Lutonix drug-eluting balloon for treating peripheral artery disease.
C.R. Bard (NYSE:BCR) is on track for an early 2015 U.S. approval of its Lutonix drug-eluting balloon, company executives said yesterday after reporting earnings growth that topped expectations.
Covidien says its exposure to a raft of product liability lawsuits filed over pelvic mesh products increased by some $131 million during its fiscal 3rd quarter.